PDF下载 ( 120 KB)
Long-term effect and safety of Lamivudine in chronic hepatitis B virus infection
-
摘要: 研究拉米夫定 （lamivudine）对慢性乙型肝炎 （慢乙肝 ）的长期疗效和安全性。 4 9例患者均用拉米夫定10 0mg/d ,疗程 1～ 2年。疗效评估包括临床症状和体征、肝功能、HBV复制的指标。治疗 3～ 6个月时 ,HBV -DNA阴转率为 87 8%～ 75 5 % ,2年时降至 4 0 9%。疗程结束时HBeAg的血清转换率为 11 8%。 6个月时ALT复常率为 79 6 %。疗程结束时ALT复常率为 5 9 1%。拉米夫定治疗 6～ 9个月后可出现YMDD变异 ,随着疗程的延长YMDD变异率升高 ,YMDD变异后病情急性发作者 ,多出现HBeAg的血清转换。拉米夫定能有效抑制HBV复制 ,迅速降低血清中HBV -DNA水平 ,提高HBeAg血清转换率 ,长期服用耐受性好 ,但疗程越长YMDD变异率越高。Abstract: To evaluate the long-term effect and safety of Lamivudine in patients with chronic hepatitis B.49 patients received lamivdine 100mg daily for one to two years.The efficacy and safety were evaluated with clinical, bio-chemical, hematological and virological parameters.After 3～6 months treatment, serum levels of HBV-DNA decreased to undetectable levels in 87 8% to 75 5% of patients and 40 9% by the end of treatment The HBeAg seroconversion rates was 11 8% at the end of treatment, .ALT normalization rate was 79 6% at 6 months and 59 1% at 24 months.After 9 months treatment, YMDD mutants were detected, the risk of the mutation increases with time.However, development of the YMDD did not preclude serocon-version.After the emergence of the YMDD variants, the patients experienced acute exacerbation followed by recovery and HBeAg seroconversion.Lamivudine suppresses serum viral replication rapidly, causing reductions in serum HBV-DNA and well tolerated.However, YMDD mutants were increased with prolonged treatment.
-
Key words:
- Hepatitis B /
- Lamivdine /
- long-term effect
-
[1]YunFL , RongNC , ChauTY , etal.AcuteexacerbationandhapatitisBvirusclearanceafteremergenceofYMDDmotifmutationduringlamivudinetherapy[J].Hepatology, 1999, 30 (2) ∶567-572. [2]姚光弼, 王宝恩, 崔振宇, 等拉米夫定治疗慢性乙型肝炎病人的长期疗效[J].中华肝脏病杂志, 1999, 7 (2) , 80-83. [3]LaiCL , ChienRN , LeungNWY , etal.One-yeartrialoflamivutineforchronichepatitisB[J].NEngJMed, 1998, 339∶61-68. [4] PerilloRp, SchalmSW , SchiffEF , etal (U .S .ANetherland, Glaxow ellcome) .PredicorsofHBeAgseconversioninchronichepatitisBpa tientstreatedwithLamivudine[J].Hepatology, 1999, 30 (4, Pt.2) ∶317A . [5]HadziyannisSJ, PapatheodoridisGV , DimouE , etal.EfficacyofLong-TermLamivudineMonotherapyinPatientsWithHepatitisBeAntigen0NegativeChronicHepatitisB[J].Hepatology, 2000, 32 (4) ∶847-851. [6]杜以真, 秦来英, 范桂玲, 等干扰能和拉米夫定联合治疗慢性乙肝炎临床观察[J].临床肝胆病杂志, 2001, 5 (2) ∶121～122. [7]SchalmSW , HeathcoteJ , CianciaraJ , etal.Lamivudineandalphain terferoncombinationtreatmentofpatientswithchronichepatitisBinfection:arandomizedtrial[J].Gut, 2000, 46 (4) ∶562-568. -
本文二维码
计量
- 文章访问数: 2233
- HTML全文浏览量: 18
- PDF下载量: 764
- 被引次数: 0
下载:
